Performance of Serum AFP-L3 and PIVKA-Ⅱ in Differential Diagnosis of Benign and Malignant Liver Disease in High Risk Population

VernacularTitle:AFP-L3和PIVKA-Ⅱ检测对高危人群良恶性肝病的鉴别诊断价值
Author: Chuanshang ZHUO ; Lijuan LIU ; Shuyan ZHOU
Keywords: primary hepatic carcinoma; cirrhosis; chronic hepatitis B; AFP-L3; PIVKA-Ⅱ
From: Journal of Modern Laboratory Medicine 2017;32(4):40-42,46
CountryChina
Language:Chinese
Abstract: Objective To explore the performance of serum AFP-L3 and PIVKA-Ⅱ in differential diagnosis of benign and malignant liver disease in high risk population.Methods The serum levels of AFP-L3 and PIVKA-Ⅱ in 48 patients with primary hepatic carcinoma,43 patients with cirrhosis and 81 patients with chronic hepatitis B were analyzed retrospectively.Results There was no statistically different significance among the median levels of serum AFP in primary hepatic carcinoma patients,cirrhosis patients and chronic hepatitis B patients (x2=4.014,P=0.134).Both median level of AFP-L3 and PIVKA-Ⅱ in primary hepatic carcinoma patients were higher than cirrhosis patients and chronic hepatitis B patients (x2 =33.93,52.33,both of P values were below 0.001).The specificity (92.74％) of AFP-L3 and the sensitivity (79.17％) of PIVKA-Ⅱ were all higher.The accuracy (84.88％) of combined detection in series was the highest,with its 47.92％ of sensitivity and 99.19％ of specificity.Conclusion Combined detection PIVKA-Ⅱ and AFP-L3 series will help to differential diagnosis of benign and malignant liver disease in high risk population.